Dexmedetomidine Pharmacokinetics During Continuous Renal Replacement Therapy (CRRT)
- Registration Number
- NCT01314209
- Lead Sponsor
- Helsinki University Central Hospital
- Brief Summary
The purpose of this study is to determine dexmedetomidine pharmacokinetics during continuous renal replacement therapy on critically ill patients.
- Detailed Description
Dexmedetomidine is a selective alpha-2-adrenergic agonist with sedative properties indicated for sedation of patients in the intensive care setting. ICU patients with acute kidney injury requiring renal replacement therapies frequently have changes in volume status causing alterations in drug pharmacokinetics. Although dexmedetomidine pharmacokinetics have been studied earlier on ICU patients, there is no information on its pharmacokinetics in critically ill patients needing continuous renal replacement therapy.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10
- Age ≥ 18
- Clinical need for sedation
- Acute kidney injury requiring renal replacement therapy (according to ICUs standard operating procedures)
- Severe bradycardia (HR < 50/min)
- AV conduction block II-III (unless pacemaker installed)
- Severe hepatic impairment (bilirubin > 101 umol/l)
- Pregnancy or lactation
- Age < 18
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description dexmedetomidine Dexmedetomidine -
- Primary Outcome Measures
Name Time Method Dexmedetomidine clearance by continuous venovenous hemodialysis 10 hours from the start of the dexmedetomidine infusion
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Meilahti Hospital, Division of Anaesthesia and Intensive Care Medicine, Department of Surgery, Helsinki University Central Hospital
🇫🇮Helsinki, Finland